Key Takeaways
- DARWIN Biomed raised $1.0M (Pre-Seed) from Easo Ventures, Sodena, ERREKA.
- Sector: Healthcare, Healthtech & Medtech, Technology, Software & Gaming.
- Geography: Spain.
Analysis
Navarra-based deep tech firm DARWIN Biomed has successfully closed a €1 million Pre-Seed funding round, signaling significant investor confidence in its advanced robotics solutions for healthcare. The capital infusion is earmarked to propel the clinical validation and development of its innovative assistive technology aimed at enhancing patient quality of life.
The funding journey was strategically segmented into two phases. An initial investment saw the participation of Easo Ventures and ERREKA, enabling the project's inception and early-stage technological advancement. Subsequently, Sodena joined the effort, alongside several strategic Business Angels and continued support from Easo Ventures and Adrián Jiménez Loygorri, finalizing the round and solidifying the company's financial footing.
Beyond equity, DARWIN Biomed bolstered its financial structure with public and bank financing, including a participatory loan from ENISA and additional banking facilities. This multi-pronged approach underscores the company's robust financial planning as it navigates its initial growth phase in the highly regulated medtech sector.
At the core of DARWIN Biomed's innovation is 'MICHELANGELO,' an intelligent walker leveraging assistive robotics and advanced AI. This device is engineered to significantly improve user autonomy, safety, and overall well-being, addressing critical needs in aging populations and individuals with mobility challenges. The company aims to bridge the gap between cutting-edge deep tech and tangible societal benefits.
The newly acquired funds will be strategically deployed across three key areas: rigorous clinical validation of the MICHELANGELO technology, securing essential regulatory approvals from international bodies, and initiating international expansion, with a primary focus on European and United States markets. This expansion aligns with the growing global demand for assistive technologies in healthcare.
DARWIN Biomed, currently a lean team of four, anticipates doubling its workforce within the next 18 months. This growth is projected to coincide with achieving pivotal milestones, including obtaining CE and FDA regulatory clearances and commencing commercialization efforts in the EU and the US. This aggressive timeline reflects the company's ambition to become a global leader in assistive robotics.
Adrián Jiménez Loygorri, CEO of DARWIN Biomed, expressed his commitment to leading international adoption of advanced robotics from their base in Navarra. The involvement of Easo Ventures brings venture capital expertise, while ERREKA contributes industrial capacity. Sodena's participation further strengthens the financial and strategic backing, highlighting the collaborative ecosystem supporting deep tech innovation in the region.